-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Benzinga·10/13/2026 10:26:05
Diffusion vocale
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.